Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 15, 2010Boston Scientific to Immediately Resume Distribution of COGNIS® CRT-Ds and TELIGEN® ICDs in the U.S.
Boston Scientific Corporation (NYSE: BSX) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the two...
-
Apr 15, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2010...
-
Mar 18, 2010Company's CRT-Ds recommended for asymptomatic and mild heart failure patients
Boston Scientific Corporation (NYSE: BSX) today announced that the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA)...
-
Mar 16, 2010Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System
Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the Small Vessel and Long Lesion trials of its...
-
Mar 15, 2010Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberte® Stents in AMI patients
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of one-year subset data from the HORIZONS AMI trial...
-
Mar 15, 2010
Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PERSEUS clinical program that demonstrated...
-
Mar 15, 2010
Boston Scientific Corporation (NYSE: BSX) announced today that it has stopped shipment and is retrieving field inventory of all its implantable...
-
Mar 11, 2010First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Express® LD Iliac...
-
Mar 10, 2010Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the 59th Annual...
-
Feb 23, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming RBC Capital Markets Health Care Conference in New York City....
-
Feb 10, 2010
Boston Scientific Corporation (NYSE: BSX) today rebutted an article published in the journal HeartRhythm. The article reported a case summary of...
-
Feb 10, 2010New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness
Boston Scientific Corporation (NYSE: BSX) today announced a series of management changes and restructuring initiatives designed to strengthen the...
-
Feb 10, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2009, as well...
-
Feb 1, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of three patent disputes with Johnson & Johnson (J&J). The disputes date...
-
Jan 20, 2010
Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. District Court for the District of Delaware has found all four patents in a...
-
Jan 19, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 14, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that the first patient has been enrolled in a clinical trial to...
-
Jan 8, 2010Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms
Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Jan 5, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming J.P. Morgan Health Care Conference in San Francisco. Ray...
-
Jan 5, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its MAPS™ clinical trial, which is studying the...
-
Jan 4, 2010Company to contribute data to industry-sponsored Dual Antiplatelet Therapy (DAPT) Study
Boston Scientific Corporation (NYSE: BSX) today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study...
-
Dec 23, 2009
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...
-
Dec 16, 2009
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Nelda Connors as a Director. Ms....
-
Dec 14, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the completion of a public offering of $2 billion aggregate principal amount of its...
-
Dec 10, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the pricing of a public offering of $2 billion aggregate principal amount of its senior...
-
Nov 23, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, December 1-2. Ray Elliott,...
-
Nov 20, 2009Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug...
-
Nov 10, 2009Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention
Boston Scientific Corporation (NYSE: BSX) today announced its official sponsorship of "World Diabetes Day" for the second year in a row. The...
-
Nov 9, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its schedule of events at the 38th annual Global Congress for Minimally Invasive...
-
Nov 9, 2009COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its COGNIS® cardiac resynchronization therapy defibrillator (CRT-D) and...
-
Nov 6, 2009Company updates third quarter financial results and full-year 2009 guidance
Boston Scientific Corporation (NYSE: BSX) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ)...
-
Nov 2, 2009Third-generation drug-eluting stent now available in CE Mark countries
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent...
-
Oct 19, 2009
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...
-
Oct 9, 2009
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Oct 6, 2009Three models of stenting system now available for palliative treatment of malignant common bile duct strictures
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
-
Oct 5, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new...
-
Sep 29, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the...
-
Sep 25, 2009
Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from the HORIZONS-AMI trial. The trial,...
-
Sep 23, 2009Results support benefits of paclitaxel-eluting stents in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE...
-
Sep 22, 2009Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of...
-
Sep 21, 2009Both drug-eluting stents performed well in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue...
-
Sep 21, 2009
Boston Scientific Corporation (NYSE: BSX) today announced release of its CE-Marked, next-generation iLab System Software for the iLab® Ultrasound...
-
Sep 18, 2009PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent
Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical...
-
Sep 16, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research...
-
Sep 14, 2009Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health NetworkAgreement promotes access to testing solutions for female urinary incontinence
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a co-marketing agreement with Bladder Health Network, a...
-
Sep 10, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference, September 14-15. Ray...
-
Sep 4, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Thomas Weisel Partners 2009 Health Care Conference, September 9 - 11....
-
Sep 2, 2009
Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous...
-
Sep 1, 2009
Boston Scientific Corporation (NYSE: BSX) today announced long-term data from the Prevention of Sudden Cardiac Death II registry...
-
Sep 1, 2009Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC
Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the...